A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

Starting soon · Phase 2

Conditions studied: Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies

In brief

Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.

Key facts

Study ID

NCT07709000

Run by

Merck Sharp & Dohme LLC

People needed

60

Starts

2026-08-21

Expected to finish

2033-11-16

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) active disease that is relapsed/refractory (r/r) to prior therapy.
• Has confirmed CD19-positive disease.
• If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy.
• If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load.
• If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.

You may not qualify if…

• Has a history of serious cardiovascular and cerebrovascular diseases.
• Has a history or presence of central nervous system disease.
• Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• Has a diagnosis of immunodeficiency.
• Has a known additional malignancy that is progressing or required active treatment within the past 2 years.
• Has active autoimmune disease (not related to underlying leukemia diagnosis) that required systemic treatment in the past 2 years.
• Has any active acute graft versus host disease (GvHD) or active chronic GvHD requiring systemic treatment.
• Has active infection requiring systemic therapy.
• Has not adequately recovered from major surgery or has ongoing surgical complications.
• Has a diagnosis of Richter Transformation.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.